These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11142690)

  • 21. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miltefosine in recurrent cutaneous breast cancer.
    Clive S; Leonard RC
    Lancet; 1997 Mar; 349(9052):621-2. PubMed ID: 9057742
    [No Abstract]   [Full Text] [Related]  

  • 23. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
    Bäumer W; Wlaź P; Jennings G; Rundfeldt C
    Eur J Pharmacol; 2010 Feb; 628(1-3):226-32. PubMed ID: 19917276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience.
    Bourke MG; Salwa SP; Sadadcharam M; Whelan MC; Forde PF; Larkin JO; Collins CG; O'Reilly S; O'Sullivan GC; Clover AJ; Soden DM
    Breast Cancer Res Treat; 2017 Jan; 161(2):289-297. PubMed ID: 27878392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Spectrographic studies on the radioresistance of Miltex and miltefosine].
    Bollmann G; Paukisch H; Bothe E; Strate W; Gademann G
    Strahlenther Onkol; 1997 Apr; 173(4):230-5. PubMed ID: 9148435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.
    Miles DW; Smith IE; Coleman RE; Calvert AH; Lind MJ
    Eur J Cancer; 2001 Jul; 37(11):1366-71. PubMed ID: 11435066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
    Fumoleau P; Delgado FM; Delozier T; Monnier A; Gil Delgado MA; Kerbrat P; Garcia-Giralt E; Keiling R; Namer M; Closon MT
    J Clin Oncol; 1993 Jul; 11(7):1245-52. PubMed ID: 8315421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
    Verweij J; Planting A; van der Burg M; Stoter G
    J Cancer Res Clin Oncol; 1992; 118(8):606-8. PubMed ID: 1325463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
    Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
    Crul M; Rosing H; de Klerk GJ; Dubbelman R; Traiser M; Reichert S; Knebel NG; Schellens JH; Beijnen JH; ten Bokkel Huinink WW
    Eur J Cancer; 2002 Aug; 38(12):1615-21. PubMed ID: 12142051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of topical ceramides for cutaneous breast cancer.
    Jatoi A; Suman VJ; Schaefer P; Block M; Loprinzi C; Roche P; Garneau S; Morton R; Stella PJ; Alberts SR; Pittelkow M; Sloan J; Pagano R
    Breast Cancer Res Treat; 2003 Jul; 80(1):99-104. PubMed ID: 12889603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of miltefosine with intercellular membranes of stratum corneum and biomimetic lipid vesicles.
    Alonso L; Mendanha SA; Marquezin CA; Berardi M; Ito AS; Acuña AU; Alonso A
    Int J Pharm; 2012 Sep; 434(1-2):391-8. PubMed ID: 22692081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers.
    Eilender D; LoRusso P; Thomas L; McCormick C; Rodgers AH; Hooper CL; Tornyos K; Krementz ET; Parker S; Morgan LR
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):719-26. PubMed ID: 16184382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
    Mahtani RL; Stein A; Vogel CL
    Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.